Related references
Note: Only part of the references are listed.Metastatic breast cancer: The role of pegylated liposomal doxorubicin after conventional anthracyclines
Shailendra Verma et al.
CANCER TREATMENT REVIEWS (2008)
Do clinical practice guidelines (CPGs) change clinical practice? An analysis of CPG impact on referral and treatment patterns for neoadjuvant chemotherapy in bladder cancer
B. J. Miles et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment
Kathy S. Albain et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
Eva S. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancer
H. L. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer
Vernon Harvey et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer
Benny Vittrup Jensen
SEMINARS IN ONCOLOGY (2006)
Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: Results of a dutch community setting trial for the clinical trial group of the comprehensive cancer centre
M Bontenbal et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma -: Pooled analysis of 2805 patients
E Bria et al.
CANCER (2005)
Docetaxel - A review of its use in metastatic breast cancer
KA Lyseng-Williamson et al.
DRUGS (2005)
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
MER O'Brien et al.
ANNALS OF ONCOLOGY (2004)
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer
AM Keller et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase II study of pegylated liposomal doxorubicin (Caelyx®) and docetaxel as first-line treatment in metastatic breast cancer
A Alexopoulos et al.
ANNALS OF ONCOLOGY (2004)
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193)
GW Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results
J O'Shaughnessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Liposomal anthracyclines for breast cancer
JA Sparano et al.
SEMINARS IN ONCOLOGY (2001)
Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer
JA Sparano et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
A systematic overview of chemotherapy effects in breast cancer
J Bergh et al.
ACTA ONCOLOGICA (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Pegylated liposomal doxorubicin (doxil):: Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2
T Safra et al.
ANNALS OF ONCOLOGY (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
